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ABSTRACT: HIV-1 reverse transcriptase (RT) catalytically incorporates individual nucleotides into a viral DNA strand 
complementing an RNA or DNA template strand; the polymerase active site of RT adopts multiple conformational and struc-
tural states while performing this task.  The states associated are dNTP binding at the N site, catalytic incorporation of a nu-
cleotide, release of a pyrophosphate, and translocation of the primer 3’-end to the P site.  Structural characterization of each 
of these states may help in understanding the molecular mechanisms of drug activity and resistance, and in developing new 
RT inhibitors.  Using a 38-mer DNA template-primer aptamer as the substrate mimic, we crystallized an RT/dsDNA com-
plex that is catalytically active, yet translocation-incompetent in crystals.  The ability of RT to perform dNTP binding and 
incorporation in crystals permitted obtaining a series of structures – (I) RT/DNA (P-site), (II) RT/DNA/AZTTP ternary, (III) 
RT/AZT-terminated DNA (N-site), and (IV) RT/AZT-terminated DNA (N-site)/foscarnet complexes.  The stable N-site 
complex permitted binding of foscarnet as a pyrophosphate mimic.  The Mg2+ ions dissociated after catalytic addition of 
AZTMP in the pre-translocated structure III, whereas ions A and B had reentered the active site to bind foscarnet in structure 
IV.  The binding of foscarnet involves chelation with the Mg2+(B) ion and interactions with K65 and R72. Analysis of inter-
actions of foscarnet and the recently discovered nucleotide-competing RT inhibitor (NcRTI) α-T-CNP in two different con-
formational states of the enzyme provide insights for developing new classes of polymerase active site RT inhibitors. 
INTRODUCTION 
HIV-1, being a lentivirus, encodes the enzyme 
reverse transcriptase (RT) for copying the viral 
RNA into a viral dsDNA1.  The DNA is integrat-
ed into the host cell chromosome by integrase, 
another viral enzyme.  The DNA polymerization 
activity of RT is currently targeted by two classes 
of drugs that inhibit the enzyme by two distinct 
mechanisms.  Non-nucleoside RT inhibitors 
(NNRTIs) bind to a hydrophobic pocket adjacent 
to the polymerase active site of RT2,3, and an 
NNRTI functions as an allosteric inhibitor by 
perturbing the conformational state of an 
RT/nucleic acid complex4-7.  In contrast, a nucle-
oside analog RT inhibitor (NRTI) binds as dNTP 
mimic, and is catalytically incorporated into the 
primer DNA strand by RT.  All NRTIs act as 
DNA chain terminators because they lack a 3’-
OH preventing the incorporation of next nucleo-
tide.  
Currently, five NNRTIs and eight NRTIs are ap-
proved anti-AIDS drugs.  RT-inhibiting drugs are 
widely used in combinations with protease, inte-
grase, and viral entry inhibitors for treating HIV-
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1 infections.  Like other types of HIV drugs, the 
effectiveness of an RT inhibitor is compromised 
by side effects and emergence of drug resistance 
upon long-term use. Various RT mutations 
emerge to confer resistance to NRTIs and NNR-
TIs8-10.  RT confers NRTI resistance primarily (i) 
by exclusion or discrimination of an NRTI tri-
phosphate from a dNTP (M184V/I and K65R are 
examples of exclusion mutations) and (ii) by ex-
cision, which removes an incorporated NRTI 
from the primer terminus by pyrophosphorolysis. 
The AZT (1-[(2R,4S,5S)-4-azido-5-
(hydroxymethyl) oxolan-2-yl]-5-
methylpyrimidine-2,4-dione) resistance muta-
tions [D67N, K70R, L210W, T215Y/F and 
K219Q/E11, also known as AZTr, excision-
enhancing mutations (EEMs), or thymine analog 
mutations (TAMs)] facilitate binding of an ATP 
molecule to RT as a pyrophosphate donor for ex-
cision12-14.  
Periodically, new drugs are needed in the pool of 
available drugs for improving the treatment op-
tions for patients facing adverse side effects or 
resistance challenges to current drugs.  Effective 
(i) nucleotide-competing RT inhibitors (NcRTIs) 
that compete with dNTP binding15,16, or (ii) pyro-
phosphate mimics that would prevent pyrophos-
phorolysis/excision have potential for being de-
veloped as new classes of RT-inhibiting drugs.  
Foscarnet (phosphonoformic acid, PFA), a pyro-
phosphate mimic, is used to treat cytomegalovi-
rus (CMV) eye infection in patients with AIDS.  
PFA is also used to treat herpes simplex virus 
(HSV) infections of the skin and mucous mem-
branes in immunocompromised persons17,18 when 
they do not respond to other therapies.  HIV-1 
RT, like other DNA polymerases, is inhibited by 
PFA at an IC50 in the sub-micromolar range19.  
PFA retains its potency against HIV-1 RT carry-
ing NRTI and NNRTI resistance mutations20,21.  
PFA is not, however, routinely used clinically to 
treat HIV infection, likely due to a modest inhibi-
tory effect.  Optimization and elaboration of the 
PFA scaffold may help in developing more po-
tent RT-specific drugs for treating HIV-1 infec-
tion. 
Based on biochemical studies22-24 and a crystal 
structure of PFA in complex with an engineered 
chimeric DNA polymerase (UL54) of CMV25, 
PFA is expected to bind HIV-1 RT mimicking 
the β, γ−pyrophosphate moiety of a dNTP.  Our 
earlier attempts to obtain a crystal structure of an 
RT/DNA/PFA complex were not successful us-
ing either cross-linked or non-cross-linked 
RT/DNA N-site complexes14,26.  A primary chal-
lenge was to stabilize an N-site RT/nucleic acid 
binary complex to which PFA is expected to 
bind24.   
Figure 1.  Structural states of HIV-1 RT trapped in 
crystals of RT/apt-DNA. The crystals of an RT/apt-DNA 
complex (I) were soaked with AZTTP and CaCl2 for the 
formation of an RT/apt-DNA/AZTTP complex (II); N and 
P sites are indicated in I.  Crystals of I were soaked with 
AZTTP and MgCl2 for catalytic addition of AZTMP result-
ing in complex III.  Crystals of III were further soaked 
with PFA and MgCl2 for the formation of the RT/apt-
DNA/PFA complex (IV). 
Using a modified SELEX (selective evolution of 
ligands by exponential enrichment) approach, 
template-primer sequences that bind HIV-1 RT 
with high affinity were selected27.  Further modi-
fication of these sequences led to the construction 
of a 38-mer hairpin DNA aptamer (apt-DNA) 
that bound HIV-1 RT with very high affinity28.  
This aptamer binds RT as a 15 base-pair duplex 
extending from the polymerase active site to-
wards the RNase H domain, a three-
deoxythymidine hairpin loop proximal to the 
RNase H domain, and a five-nucleotide 5’-
overhang29.  Here we demonstrate that the 
RT/apt-DNA complex is catalytically active, 
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permitting the binding of AZTTP as a dNTP ana-
log and subsequently incorporating AZTMP at 
the 3’-end (Figure 1) in crystals.  However, 
translocation of the DNA was restricted by the 
aptamer hairpin that is locked against the RNase 
H domain of RT, and this stable N-site complex 
in crystals permitted the binding of PFA as a py-
rophosphate mimic. The RT/apt-DNA P-site 
complex permitted the binding of α-T-CNP16 by 
coordinating with both catalytic metal ions.  The 
binding of α-T-CNP and PFA to RT reveals two 
distinct conformations of the polymerase active 
site with different chelating environments for de-
signing novel RT inhibitors. 
RESULTS AND DISCUSSION 
AZTTP binding and incorporation into apt-
DNA by RT in crystals. The structure of the 
RT/apt-DNA complex (I) was recently reported 
at 2.3 Å resolution, revealing that the binding 
mode of the aptamer is similar to that of previ-
ously reported cross-linked RT/DNA complexes 
at and near the polymerase active site29. RT/DN 
A cross-linking were performed in conjunction 
with catalytic addition of one dideoxynucleotide 
at the primer 3’-end30,31. In fact, most reported 
DNA polymerase pre-catalytic complex struc-
tures have been determined with 3’-dideoxy-
terminated nucleic acid.  In contrast, the complex 
I has a 3’-OH group that is positioned at the pol-
ymerase active site for binding and catalytic addi-
tion of the next nucleotide, which is a dTTP or 
related analog.  Ca2+ ions are not efficient cations 
for DNA polymerization by RT.  We soaked 
AZTTP and CaCl2 into crystals of I for the for-
mation of a ternary complex without incorpora-
tion.  As described in the experimental section, a 
short (5-minute) soak formed a ternary 
RT/DNA/AZTTP (II) complex in the crystal, and 
the structure of the complex was determined at 
3.3 Å resolution (SI Table 1).  The AZTTP binds 
at the N site in a mode that is analogous to the 
previously obtained mode of binding in 
RT/dsDNA/AZTTP (or dTTP) complex struc-
tures (Figures 2A & B)6,30.  A Ca2+ ion is present 
at the metal B site and chelates one oxygen from 
each of the three phosphates of AZTTP; no ion is 
present at the A site. Even though the 3’-end of 
apt-DNA had an OH group present for incorpora-
tion of the incoming AZTMP, the use of Ca2+ 
ions was not efficient for carrying out the cataly-
sis in the crystal within the 5-minute soaking 
time. 
Fig. 2. Binding and incorporation of AZT-TP by RT in 
crystals.  A. AZTTP (yellow) is bound at the polymerase 
active site in RT/apt-DNA/AZTTP complex (II). B. The 
ternary structures of RT/apt-DNA/AZTTP and 
RT/DNA/AZTTP (PDB ID. 3V4I; cyan) are highly super-
imposable at the polymerase active site. C. The polymerase 
active site region after incorporation of AZTMP in the 
RT/apt-DNA (AZTMP terminated) N-site structure (III). D. 
Location of incorporated AZTMP with respect to the cata-
lytic triad of aspartates.  
Soaking a crystal in 2.8 mM AZTTP with 25 mM 
MgCl2 for 10 minutes, however, confirmed our 
hypothesis that the RT/apt-DNA complex is in-
deed catalytically active by incorporating an 
AZTMP at the 3’-end of the apt-DNA (Figures 
2C & D). Serendipitously, the incorporated 
AZTMP does not translocate from the N site to 
the P site because the DNA hairpin is locked 
against the RNase H domain of RT at the oppo-
site end, preventing the sliding of DNA in the 
crystal.  The crystal packing analysis (SI Figure 
1) did not indicate any noticeable interaction of 
apt-DNA with symmetry related molecules.  Un-
like a typical RT/DNA complex, which can be 
highly dynamic in solution32, the RT/apt-DNA 
apparently forms a stable complex with enhanced 
protein-nucleic acid interactions. The RT/apt-
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DNA-AZTMP (III) structure represents a state of 
RT/DNA complex following catalytic incorpora-
tion of a dNTP that precedes translocation.  In 
this pre-translocation N-site state (III), the Mg2+ 
ions are dissociated from the polymerase active 
site after the catalytic addition of AZTMP, and 
two catalytic aspartates D110 and D186 are 
pointing away from nucleic acid at the active site.  
The phosphate oxygens of the newly formed 
phosphodiester bond are in close proximity to 
both carboxyl oxygens of the third catalytic as-
partate D185 (Figure 2D).  In a typical 
RT/nucleic acid complex, this congregation of 
negatively charged groups would either (i) repel 
to facilitate the nucleic acid translocation or (ii) 
attract cations to stabilize the N state and facili-
tate pyrophosphorolysis, as discussed below.  
PFA binding to the RT/apt-DNA complex. 
PFA as a pyrophosphate mimic is expected to 
bind and stabilize an N-site complex22,23.  Com-
plex III in the crystal was used to obtain the 
structure of the RT/DNA/PFA (IV) complex.   
We soaked crystals of complex III in a solution 
containing 5 mM PFA and 25 mM MgCl2 for 10 
minutes to enable formation of the RT/DNA/PFA 
ternary complex IV (SI Table 1).  Compared to 
complex III, in which the catalytic ions were dis-
sociated from the polymerase active site, the 
binding of PFA importantly recruited both cata-
lytic Mg2+ ions A and B to the polymerase active 
site in IV (Figures 3A & B).  One oxygen each 
from the phosphate and carboxyl groups of PFA 
chelate metal B.  Chelation of the phosphate of 
AZTMP, the main-chain carbonyl oxygen of 
V111, and one side-chain oxygen each from the 
catalytic residues D110 and D185 complete the 
octahedral coordination for metal B.  Apart from 
the metal ion chelation, the conformation of RT 
did not undergo any significant alteration in 
changing from III to IV upon PFA binding. 
In comparison to the binding of a dNTP, the 
phosphate and the carboxyl oxygens of PFA ap-
proximately substitute for the chelating oxygens 
of β,γ-pyrophosphate, respectively; however, the 
positions of the chelating atoms are not superim-
posable (Figure 3C).  The mode of chelation of 
PFA to RT is switched when compared with that 
observed in the structure of engineered chimeric 
DNA polymerase UL54 complex (Figures 3D & 
E)25.  This preferred orientation of PFA in the RT 
complex is apparently steered by a network of 
interactions of the phosphate group with RT be-
yond the metal interaction site.  The interactions 
are (i) with the main-chain amide group of D113, 
adjacent to the polymerase active site and (ii) a 
salt bridge between the two non-chelating ox-
ygens of the phosphate group of PFA and the 
guanidinium group of R72 (Figure 3F); R72 is a 
highly conserved amino acid residue that is es-
sential for polymerization33. Additionally, the 
side chain of K65 interacts with the non-chelating 
oxygen of the carboxyl group of PFA.  PFA has 
been reported to facilitate the removal of AZTMP 
from the 3’-end of the DNA primer34.  Position-
ing of the phosphate group of PFA near the phos-
phodiester bond of incorporated AZTMP in com-
plex III may facilitate the excision only when the 
phosphate group of PFA is oriented in-line as an 
excision agent.  However, the PFA orientation in 
III is not appropriate to initiate excision despite 
the close proximity of the phosphate group to the 
phosphodiester bond (Figure 3C).   
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Figure 3. Binding of PFA. A. A schematic view of transi-
tion at the polymerase active site upon binding of PFA 
(from complex III to IV).  B. Difference Fo - Fc (magenta) 
and 2Fo - Fc (blue) electron density maps at 3 Å resolution 
revealed the PFA binding mode and polymerase active-site 
conformation.  C. Superposition of structures II and IV 
shows the positional differences of chelating oxygen atoms 
of PFA compared to the pyrophosphate moiety (β and γ 
phosphates) of AZTTP.  Comparison of the binding modes 
of PFA with HIV-1 RT (D) and with engineered chimeric 
DNA polymerase UL54D25 (E). F.  Interactions of PFA 
with RT. The sites of PFA-resistance mutations K65R and 
A114S are in cyan.  G. Electrostatic potential surface of RT 
and location of PFA in the complex. 
PFA resistance.  Commonly observed RT muta-
tions associated with PFA resistance are K65R, 
W88G/S, E89K, A114S, S117T, Q161L, M164I, 
and Q161L/H208Y22,35-37.  Residue K65 interacts 
with PFA in structure IV.  The K65R mutation 
influences the positioning of amino acids R65 
and R7238, and this structural rearrangement 
would interfere with the observed interactions of 
the two amino acid residues K65/R72 with PFA 
(Figures 3F & G).  Residue A114 is positioned 
adjacent to the phosphate group of PFA or the 
β−phosphate group of a dNTP substrate, and the 
side chain of S114 in an A114S mutant RT would 
perturb the position and/or charge distribution of 
the phosphate group.  The remaining RT muta-
tions are located away from PFA, and would in-
terfere indirectly with PFA binding presumably 
by reducing the stability of the N-site complex or 
by interfering with the positioning of the two 
metal ions.  The amino acid residue stretch 88–95 
interacts with the template strand adjacent to the 
polymerase active-site, and mutations in this 
stretch affect fidelity of RT39.  Mutations at posi-
tions 88 and 89 are likely to perturb the position-
ing of the template strand. 
Most of the PFA-resistance mutations reduce the 
pyrophosphorolysis by RT, i.e., the mutations 
either directly interfere with the binding of pyro-
phosphate or indirectly reduce the stability of an 
N-site RT complex.  Thereby, the PFA-resistance 
mutations reduce the ability of RT to excise 
AZTMP and, consequently, improve AZT sensi-
tivity even in the presence of AZT-resistance mu-
tations (EEMs).  Structurally, it has been shown 
that the EEMs primarily enhance the binding af-
finity of ATP as a pyrophosphate donor.  As ex-
pected, comparison of the complex IV with the 
structure of the RT/DNA/AZTppppA excision 
product complex14 shows that PFA would inter-
fere with the binding/positioning of the pyro-
phosphate moiety of an ATP.  In such a scenario, 
the pyrophosphate moiety would not be able to 
reach the active site even if EEMs enhance the 
binding of the base-ribose moiety of ATP to RT.  
Binding of α-T-CNP.  Unlike PFA, the NcRTI 
α-CNP binds as a dNTP mimic at the N site.  
There are important differences, however, in the 
interactions and chelation geometry for α-T-CNP 
compared to dTTP (or AZTTP).  Recently, we 
reported the structure of α-T-CNP in complex 
with a cross-linked RT/DNA16, in which cation A 
was not present at the polymerase active site pri-
marily due to the use of a dideoxy-terminated 
primer.  The structure of the RT/apt-DNA/α-T-
CNP complex (V) determined at 2.75 Å resolu-
tion (SI Table1), however, confirm the presence 
of both metal ions at the polymerase active site 
and reveals the complete coordination of the in-
hibitor (Figure 4A).  
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Figure 4.  Binding of α-T-CNP and PFA to RT.  A. Su-
perposition of α-T-CNP (cyan) in the RT/DNA cross-
linked complex (PDB Id. 4R5P)16 on to the RT/apt-DNA/α-
T-CNP complex (inhibitor, yellow; protein, gray).  The 
current structure reveals coordination of α-T-CNP with 
both Mg2+ ions.  B. Active site superposition of structures 
IV and V shows the relative positioning and metal chela-
tion of PFA (green) and α-T-CNP (yellow); only the che-
lating oxygen atoms are colored red. 
The structures IV and V, both being in one crys-
tal form, provide a direct comparison of the bind-
ing of α-T-CNP and PFA to RT (Figure 4B); the 
first one as a dNTP- and the second one as a py-
rophosphate-competing inhibitor, respectively.  
PFA binds only when the primer terminus is at 
the N site, and α-T-CNP binds only when the 
primer terminus is at the P site, i.e., binding of 
the two inhibitors is mutually exclusive.  Howev-
er, each of the two inhibitors is expected to com-
plement AZT in inhibiting RT because either one 
can bind when AZT is a chain terminator.  AZT 
and PFA have earlier been demonstrated to act 
synergistically against HIV in cell culture19,40,,41 
and AZTTP has also been claimed to synergisti-
cally inhibit HIV-1 RT when combined with 
PFA41, but only at their IC90 or IC95 concentra-
tions, whereas antagonistically or additively in-
hibiting the enzyme when combined at IC50 or 
IC75 concentrations, respectively.  These observa-
tions demonstrate the complexity of drug combi-
nations42, and also revealed a mutually exclusive 
inhibition of HIV-1 RT by AZTTP and PFA.  
Potential antiviral synergy between AZT (or 
PFA) and α-CNPs could not be tested since the 
current α-CNPs are not efficiently taken up by 
HIV-infected cells.  Therefore, combinations of 
AZTTP with PFA, AZTTP with T-α-CNP, and 
PFA with T-α-CNP have been investigated for 
their inhibition of RT activity over a broad range 
of inhibitor concentrations (SI Figure 2).  No 
dramatic differences were observed in the degree 
of increased potencies of the anti-HIV-1 RT ac-
tivity when any of the inhibitors was combined 
with one of the other inhibitors.  The combination 
index (CI) versus fractional inhibition values, and 
normalized isobolograms (SI Figure 3) for the 
three different inhibitor combinations revealed 
additive to modest synergistic activities in all 
three cases, with somewhat lesser effect for the 
PFA/T-α-CNP combination.  It should, however, 
be noticed that the RT assays were conducted in a 
cell-free system under artificial conditions.  The-
se results may reflect the dynamic states of an 
RT/DNA complex in solution that did not permit 
trapping the RT/DNA/PFA complex when the 
special apt-DNA was not used in the assay.  Im-
proved inhibitors with higher binding affinity 
may form more stable complexes. 
Drug design.  The active-site region of an en-
zyme in general is less susceptible to mutation, 
and therefore represents a highly valuable target 
for drug discovery.  Information on the precise 
metal chelation geometry43 and the surrounding 
environment can help in designing target-specific 
inhibitors.  Derivatives of 4-chlorophenyl	 hy-drazine	mesoxalic	acid	(CPHM) have been iden-
tified as translocation inhibitors44,45.  Analogous 
to PFA, CPHM compounds are predicted to pref-
erentially bind to N-site complexes of RT.  De-
spite both inhibitors chelating the polymerase 
active site cations, the interactions of the distinct 
side groups with RT define their respective bind-
ing affinity and impacts of resistance mutations; 
K65R mutation favors CPHM binding and devel-
ops resistance to PFA.  K65R mutation forms a 
guanidinium platform with R7238, and the plat-
form presumably stacks favorably with the aro-
matic side group of CPHM.  The malonate group 
of CPHM might chelate Mg2+ ions of an N com-
plex in a mode analogous to the structurally ob-
served mode of chelation of a malonate-
containing NcRTI to the P complex (PDB ID  
5HLF)46.  In the context of antiviral activity, PFA 
inhibits HIV, whereas, the malonate-containing 
NcRTI and CPHM fail to exhibit antiviral re-
sponse presumably because of their inability to 
penetrate the cell wall.  The comparison of PFA 
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and CPHM in inhibiting RT suggests that chemi-
cal modifications of the compounds binding to 
the N or P complex could be exploited for im-
proved RT binding and cellular uptake. 
Additionally, the individual conformational states 
of the active site of RT can ideally be targeted 
and trapped by small molecules.  Active-site 
metal-chelating inhibitors, such as the HIV-1 in-
tegrase-inhibiting drugs raltegravir, elvitegravir, 
and dolutegravir, chelate the catalytic metal ions 
of the intasome complex to block strand 
transfer47,48.  A systematic elaboration from the 
metal-chelating diketo acid moiety helped gain 
specificity and efficacy even in the absence of 
any three-dimensional structural information47.  
In an analogous platform, knowledge of the bind-
ing and chelation of PFA or α-T-CNP at the pol-
ymerase active site of RT provides opportunities 
for developing new RT-inhibiting drugs.  In 
agreement with the existing biochemical data, the 
structural data show that PFA binding stabilizes 
the N-site complex, and PFA binding would in-
hibit pyrophosphorolysis as a pyrophosphate-
competing inhibitor.  Mutations that would re-
duce the binding of PFA are likely to reduce the 
binding of a pyrophosphate donor and excision.  
Therefore, either the presence of PFA or PFA-
resistance mutations, in general, suppresses AZT 
resistance both in viral and enzymatic studies37,49.  
RT has to compromise its activity for developing 
resistance to PFA, however, the binding affinity 
of PFA to RT is modest due to the lack of RT-
specific interactions.  The structure of IV reveals 
the conformational state of RT and the molecular 
interactions between RT and PFA.  Chemical 
elaboration of the PFA backbone aided by 
knowledge of the structure may lead to improved 
pyrophosphate-mimicking inhibitors.  Combining 
structural features of α-T-CNP/AZTTP at the N-
site and PFA (Figure 4B) may help to develop 
novel high-affinity NcRTIs that can exhibit anti-
viral activity. 
CONCLUSIONS 
A special 38-mer DNA aptamer permitted obtain-
ing the crystal structure of a highly stable HIV-1 
RT/DNA complex (I)29, and the crystals were 
used to obtain the structures with bound AZTTP 
(II), AZT-MP incorporated at the N site (III), 
and PFA bound to an N-site complex (IV) (Fig-
ure 1).  Also, a structure of the NcRTI, α-T-CNP 
(V), chelating both catalytic Mg2+ ions at the pol-
ymerase active site of RT, is reported here for the 
first time.  This series of structures illuminate 
multiple conformational states of the polymerase 
site that HIV-1 RT would undertake for pro-
cessing nucleotide addition or pyrophosphoroly-
sis.  The structural knowledge of these distinct 
states of the active site may enhance understand-
ing the molecular mechanisms of various drug-
resistance mutations and help in targeting DNA 
polymerization by new classes of active-site-
chelating inhibitors.  
MATERIALS AND METHODS 
Reverse transcriptase assay with homopoly-
meric template-primers.  HIV-I RT assays were 
carried out in the presence of the artificial homo-
polymeric template-primer poly(A)dT12-18 (oli-
go(dT), Pharmacia, Uppsala, Sweden).  To pre-
pare the template-primer for the RT inhibition 
experiments, 0.15 mM poly(A) was mixed with 
an equal volume of 0.0375 mM oligo(dT).  The 
reaction mixture (50 µl) contained 50 mM 
TrisHC1 pH 7.8, 5 mM dithiothreitol, 300 mM 
glutathione, 500 µM EDTA, 150 mM KCl, 5 mM 
MgCl2, 1.25 µg of bovine serum albumin, an ap-
propriate concentration of the tritium-labeled 
substrate [CH3-3H]dTTP (2 µCi/assay; 2 µM), a 
fixed concentration of the template-primer 
poly(A).oligo(dT) (0.015 mM), 0.06% Triton X-
100, 10 µl of AZTTP, T-α-CNP and/or PFA  in-
hibitor solution (containing various concentra-
tions of the compounds or dual combinations 
thereof), and 1 µl of the HIV-1 RT preparation.  
The reaction mixtures were incubated at 37 °C 
for 30 minutes, at which time 100 µl of calf thy-
mus DNA (150 µg/ml), 2 ml of Na4P207 (0.1 M in 
1 M HCl), and 2 ml of trichloroacetic acid (10% 
v/v) were added.  The solutions were kept on ice 
for 30 minutes, after which the acid-insoluble 
material was washed and analyzed for radioactiv-
ity.  The inhibition data were processed using 
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CompuSyn software.  Synergism, additivity, or 
antagonism was determined by calculation of the 
combination index (CI) values.  A CI<0.95 indi-
cates synergism, >1.05 antagonism, and between 
0.95 and 1.05 represents additivity according to 
Kong et al.42 and Chou and Talalay50. 
Crystallography. RT purification and crystalli-
zation with apt-DNA were carried out using ear-
lier described experimental conditions29.  Crystals 
of RT/apt-DNA (I) complex were soaked in the 
crystallization solution containing 25 mM CaCl2 
and 2.8 mM AZTTP for 5 minutes for the for-
mation of RT/apt-DNA/AZTTP ternary complex 
(II).  Crystals of I were soaked with 25 mM 
MgCl2 and 2.8 mM AZTTP for 10 minutes, and 
the condition was suitable for catalytic incorpora-
tion of AZTMP at the 3’-end of the apt-DNA by 
RT to form the RT/AZT-terminated apt-DNA N-
site complex (III).  Crystals of III were then 
soaked in a solution containing 25 mM MgCl2 
and 5 mM PFA for 1 hour for the formation of 
RT/apt-DNA/PFA ternary complex (IV).  Crys-
tals of I were soaked in a solution containing 25 
mM MgCl2 and 2 mM α-T-CNP for the for-
mation of RT/apt-DNA/α-T-CNP ternary com-
plex (V).  All crystal soaking solutions contained 
10% (w/v) PEG 8000, 25 mM Bis-tris propane 
pH 6.8, 75 mM Bis-tris propane pH 7.4, 50 mM 
ammonium sulfate, 5% (v/v) glycerol, and 5% 
(w/v) sucrose.  The cryoprotectant solutions in 
which the crystals were dipped prior to flash 
cooling were made from the respective soaking 
solution by increasing the glycerol concentration 
to 25% (v/v).  X-ray diffraction data were col-
lected using synchrotron beam lines; the initial 
structures were solved using the structure of 
RT/apt-DNA complex (PDB ID 5D3G ) as the 
starting model.  The structures were refined using 
Phenix51 and the model building was carried out 
using Coot52.  The crystallographic data and re-
finement statistics are listed in SI Table 1, and 
the coordinates and structure factors were depos-
ited in the PDB under accession codes 5I42, 
5I3U, 5HP1, and 5HRO for structures II to V, 
respectively. 
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